Desq Long
Sign in

Company

Damora Therapeutics, Inc.

DMRA · CIK 0001800315

SEC FORM 4
$252,875.00

Damora Therapeutics, Inc. (DMRA)

Purchase of 12,500 shares at $20.23 per share.

Reporting Person Jarrett Jennifer · Officer Title Director, President and CEO · Transaction Code P

Traded Sep 25, 2026 · Disclosed Sep 28, 2026

Source: SEC Form 4 · 0001193125-26-403355 · filed 2026-09-28 · View filing →